Gritstone posts 'one of the most potent immunogenic-responses for a neoantigen vaccine'

Presenting at the European Society for Medical Oncology Immuno-Oncology Congress in Geneva, cancer vaccine biotech Gritstone said its phase 1 test of immunogenicity data showed a “rapid, robust and consistent induction of large numbers of CD8+ T cells against multiple neoantigens in four solid tumor patients with available IFN-g ELISpot data (up to 3,000 IFN-g spot forming units per 106 PBMCs were generated, as measured by overnight ELISpot)” within the first two dosing cohorts.